American Association of Plastic Surgeons
Total Page:16
File Type:pdf, Size:1020Kb
HEART VALVE SOCIETY 2017 Annual Meeting March 2-4 2017 Grimaldi Forum Monte Carlo, Monaco THURSDAY, MARCH 2ND 08.25 – 08.30 Welcome and Opening of the 3rd Scientific Meeting of the Heart Valve Society Camille Blanc Gilles Dreyfus, MD, President of the Heart Valve Society 08.30 – 09:45 Opening Plenary Session Camille Blanc Moderator: Gilles Dreyfus, MD 08.30 – 08.45 Valve Leaflet Thrombosis Post-TAVI: A Mirage or a Reality? Carlos Ruiz, MD 08.45 – 09.00 Is there a risk in avoiding risk? Hanneke Takkenberg, MD, PhD 09.00 – 09.15 TAVR vs. Surgery in 2017: When Less is More and When More is More! Martin Leon, MD 09.15 – 09.30 Translating Heart Valve Tissue Engineering to the Clinic Simon Hoerstrup, MD, PhD 09.30 – 09:45 Anticoagulation for Bioprosthetic Valves: Art or Science? Greg Fontana, MD 09:45 – 10:00 Presidential Address Camille Blanc Functional MR: Are we wrong all the way? Gilles Dreyfus, MD 10.00 – 10.30 Coffee Break & Poster Viewing 10.30 – 12.00 Concurrent Session I: Endocarditis: An ongoing challenging disease Camille Blanc Moderators: Raphael Rosenhek, MD Gilbert Habib, MD 10:30 – 10:50 Prosthetic Valve Endocarditis and Tavi Endocarditis: The Achilles Heels of TAVR Gilbert Habib, MD 10:50 – 11:10 Neurological complications Michael Borger, MD 11:10 – 11:30 IE during pregnancy Marta Sitges, MD 11:30 – 11:50 Can the guidelines solve all the problems? Raphael Rosenhek, MD 11:30 – 12:00 Discussion 10.30 – 12.00 Concurrent Session II: MitraClip: Lights and Shadows Bosio Moderators: Michele De Bonis, MD, FESC Nicola Buzzatti, MD 10.30 – 10.42 MitraClip's updates on clinical evidence Edith Lubos, MD 10.42 – 10.48 Discussion 10.48 – 11.00 MitraClip's current limitations Michele De Bonis, MD, FESC 11.00 – 11.06 Discussion 1 11.06 – 11.18 When to do it, when to avoid it: Clinical and anatomic selection for MitraClip Martin Swaans, MD 11.18 – 11.24 Discussion 11.24 – 11.36 MitraClip's role in challenging and unusual scenarios (case-based) Ralph Stephan von Bardeleben 11.36 – 11.42 Discussion 11.42 – 11.54 Should MitraClip and Surgery Compete? Francesco Maisano, MD 11.54 – 12.00 Discussion 10.30 – 12.00 Concurrent Session III: How can biomarkers optimize the timing of heart valve Poulenc surgery? Moderators: Mostafa Mokhles, MD, PhD Mare Annick Clavel, DVM, PhD 10:30 – 10:45 “Hot” Biomarkers in Aortic Disease Marie Annick Clavel, DVM, PhD 10:45 – 11:00 “Hot” Biomarkers in Mitral Regurgitation Thierry Le Tourneau, MD, PhD 11:00 – 11:15 What is the best way to measure frailty in elderly HVD patients? Volkmar Falk, MD 11:15 – 11:30 'The role of natriuretic peptides in patients with severe aortic stenosis Jutta Bergler-Klein, MD 11:30 – 11:45 Longitudinal and mixed modelling of biomarkers to optimize the timing of treatment Mostafa Mokhles, MD, PhD 11:45 – 12:00 Discussion 10.30 – 12.00 Concurrent Session IV: Percutaneous Heart Valve Therapy Keynote & Abstracts Auric 1&2 Moderator: Vinod Thourani, MD 10:30 – 10:35 Session Keynote Vinod Thourani, MD Presenter is allowed 5 minutes for presentation followed by 3 minutes of discussion and questions 10 Abstracts 10.30 – 12.00 Concurrent Session V: Tissue Engineering Heart Valves Keynote & Abstracts Apollinaire Moderator: 10:30 – 10:35 Session Keynote Presenter is allowed 5 minutes for presentation followed by 3 minutes of discussion and questions 10 Abstracts 2 10.30 – 12.00 Concurrent Session VI: Rheumatics Disease: Advances and Innovations Scotto Moderators: Taweesak Chotivatanapong, MD Jose Pomar, MD 10.30 – 10.45 Rheumatic Valvuler Disease: Current Burden and Strategy of Management. Shahbudin H Rahimtoola, MD – need to be replaced 10.45 – 11.00 Long Term Results of Rheumatic MV Repair Gebrine El Khoury, MD 11.00 – 11.15 What to Do with Tricuspid Valve Problem: Current Understanding and Management Giles Dreyfus, MD 11.15 – 11.30 Innovative Approaches for Repairing Calcified Stenotic MV Taweesak Chotivatanapong, MD 11.30 – 11.45 Best Choice of Prosthetic Valve Replacement in Current Era Song Wan, MD 11.45 – 12.00 Transcatheter valve for rheumatic disease: Fad or real? Jose Pomar, MD 12:00 – 13.30 Industry Lunch Symposium 1 Bosio Latest Innovation in Cardiac Surgery Supported by LivaNova 12:00 – 13.30 Industry Lunch Symposium 2 Poulenc Indications and Treatment Options for Concomitant to Mitral Patients Supported by Medtronic 12:00 – 13.30 AVIATOR Network Meeting 1 Auric 3 13.30 – 15.15 Concurrent Session I: Hot Topics in TAVR Camille Blanc Moderators: Vinod Thourani, MD Martin Leon, MD 13:30-13:42 Why TAVR will be the “standard-of- care” for the management of aortic stenosis within 5 years. Martin Leon, MD 13:42-13.54 Deciding on SAVR or TAVR based on anatomic and clinical characteristics Neil Moat, MD 13:54-14:06 New concerns associated with TAVR: From leaflet immobility to structural valve degeneration to durability issues Carlos Ruiz, MD 14:06-14:15 Panel Discussion 1415-14:27pm Alternative access strategies to transfemoral (and transapical) TAVR: From subclavian to transcarotid to transcaval to suprasternal approaches Vinod H. Thourani, MD 14:27-14:39 Valve-in-valve TAVR: Technical considerations and clinical outcomes Murat Tuzcu, MD 14:39-14:51 Transcatheter approaches to aortic insufficiency Manuel Wilbring, MD 14:51-15:01 Stroke after TAVR: Changing incidence, predictors, and the use of embolic protection Susheel Kodali, MD 15:01-15:15 Panel Discussion 13.30 – 15.00 Concurrent Session II: Should we implant biological or mechanical valves in young Bosio patients? 3 Moderators: Ismail El-Hamamsy, MD, PhD Diana Aicher, MD 13.30 – 13.45 The case for biological valves in young patients Ismail El-Hamamsy, MD, PhD 13.45 – 14.00 The case for mechanical valves in young patients Walter P Dembitsky, MD 14.00 – 14.15 Quality of life after heart valve replacement in young patients Diana Aicher, MD 14.15 – 14.30 What is the role of the Ross procedure in young adults? Mostafa Mokhles, MD, PhD 14.30 – 14.45 What do you tell young adult patients who are facing prosthetic valve selection? (Focus on women, active life and ViV) Jean Louis Vanoverschelde, MD 14.45 – 15.00 Discussion 13.30 – 15.00 Concurrent Session III: Secondary Tricuspid Regurgitation after Pervious Mitral Poulenc Surgery Moderators: Marta Sitges, MD Michael Borger, MD 13.30 – 13.45 Why did tricuspid regurgitation develop in this patient years after mitral valve surgery? Marta Sitges, MD 13.45 – 14.00 Evaluation of Tricuspid Regurgitation with Imaging: Always Reliable? Martin Swaans, MD 14.00 – 14.15 Should all patients undergoing mitral valve surgery be treated with tricuspid anuloplasty or should we make a selective approach? Michael Borger, MD 14.15 – 14.30 Advances in surgical repair of the tricuspid valve. Jerry Braun, MD 14.30 – 14.45 Will the treatment of secondary tricuspid regurgitation be percutaneous? Francesco Maisano, MD 14.45 – 15.00 Discussion 13.30 – 15.00 Concurrent Session IV: Minimally Invasive Valve and Robotic Keynote & Abstracts Auric 1&2 Moderator: Rakesh Suri, MD 13.30 – 13.35 Keynote Presenter is allowed 5 minutes for presentation followed by 3 minutes of discussion and questions 10 Abstracts . 13.30 – 15.00 Concurrent Session V: Basic Research – Valve Science and Diseases Keynote & Apollinaire Abstracts Moderator: Jordan Miller, PhD 13:30 – 13:35 Keynote Presenter is allowed 5 minutes for presentation followed by 3 minutes of discussion and questions 10 Abstracts 13.30 – 15.00 Concurrent Session VI: 101: (Lies, Damned Lies and) Statistics in Heart Valve Scotto Disease Moderators: Johanna Takkenberg, MD, PhD 4 Jeffery Borer, MD 13.30 – 13.45 What is the true prevalence of the heart valve disease and do we actually have an epidemic? Raphael Rosenhek, MD 13.45 – 14.00 All you need to know about the Heart Valve Health Technology Assessment Simone Huygens, PhD 14.00 – 14.15 How to assess the validity of the design, statics, and reported outcomes of heart valve disease studies Tom Treasure, MD 14.15 – 14.30 How to Construct Objective Performance Criteria as Acceptable Historical Controls for Regulatory Approval of New Prosthetic Heart Valves Jeffery Borer, MD 14.30 – 14.45 All you need to know about the heart valve Health Technology Assessment Johanna Takkenberg, MD, PhD 15.00 – 15.30 Coffee Break & Poster Viewing 15.30 – 17.00 Afternoon Plenary Session: Rapid Fire and Pro/Con Camille Blanc Moderator: Martin Leon, MD 15.30 – 16.20 Rapid Fire Cases Presenter is allowed 4 minutes for presentation followed by 3 minutes of discussion and questions 6 Cases Pro/Con Debates 16.20 – 16.40 Debate 1: Echo vs MRI for Paravalvular Leaks after TAVR Introduction: Murat Tuzcu, MD – 8 minutes Echo: Hector Michelena, MD – 4 minutes MRI: Carlos Ruiz, MD – 4 Minutes Discussion – 4 minutes 16.40 – 17.00 Debate 2: MitraClip vs Traditional Surgery MitraClip: Francesco Maisano, MD – 5 min Traditional Surgery: Volkmar Falk, MD – 5 mins Discussion – 10- minutes 17:00 – 17.15 Annual Business Meeting Camille Blanc 17.15 – 19:00 Welcome Reception & Moderated Poster Competition Poster Head Moderators: Marta Sitges, MD Poster Topic Judges Basic Research – Valve Science and Diseases - Jorge Solis & Harry Dietz Experimental and Computational Valve Tissue Studies - Sandra Loerakker & Jane Grande- Allen Heart Valve Imaging – Raphael Rosenhek, MD & TBD Heart Valve Outcomes - Hector Michelena & Marie Annick Clavel Heart Valve Repair - Jose Pomar & Diana Aicher Minimally Invasive Valve Surgery - Rakesh Suri & Volkmar Falk, Percutaneous Heart Valve Therapy - Martin Swaans & Michele De Bonis Tissue Engineered Heart Valves - Ulrich Stock, Max